Recall on Novo Nordisk Insulin Samples; ENDO 2022 In-Person Again

The FDA cleared the Bigfoot Unity diabetes management system, used in conjunction with Abbott’s FreeStyle Libre 2 system, for type 1 and 2 diabetes; the system translates continuously monitored glucose data into on-demand insulin dosing recommendations shown on the pen-cap screen.

Novo Nordisk issued a nationwide voluntary recall of several batches of its insulin product samples — Levemir, Tresiba, Fiasp, Novolog, and Xultophy — due to improper temperature storage.

Not only has 2.4 mg of injectable semaglutide demonstrated efficacy for weight loss, but it also may help dampen appetite, food cravings, and calorie intake, according to a study presented at the European Congress on Obesity. (MedicalXpress)

In another study from the meeting, midlife adults with obesity who underwent bariatric surgery saw a 29% reduced risk for developing cataracts versus those who didn’t opt for surgery. Although this benefit wasn’t significant for patients over age 60.

The Endocrine Society announced its annual meeting will be in-person again in 2022, taking place June 11-14 in Atlanta.

More data confirmed the mortality benefit of bariatric surgery for adults with obesity; those with diabetes who opted for surgery saw a median 9.3-year longer life expectancy than non-surgical matches. (The Lancet)

Kids with a higher BMI might see a higher risk of stroke in adulthood, even without type 2 diabetes. (ScienceDaily)

New CDC data found that women with higher educational attainment had fewer births in 2019, which was further mediated by race. Overall, total fertility rates were higher for women with a 12th grade or lower level of education. (National Vital Statistics Reports)